Beth C. Seidenberg
Sits on 6 boards. Overboarded · 6 public boards Last updated September 28, 2026
Time on boards
- Boards served
- 6
- Current seats
- 6
- Board service
- 16 years
- Director since
- 2023
16 years of board service in total across 6 boards, counting each seat separately. Longest: Vera Therapeutics Inc., 3 years.
Vera Therapeutics Inc.
Director
Progyny Inc.
Director
Atara Biotherapeutics Inc.
Director
Sagimet Biosciences Inc.
Director
Kyverna Therapeutics Inc.
Director
Latigo Biotherapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | Latigo Biotherapeutics Inc. | Derivative conversion | +938,979 | — | — |
| Aug 10, 2026 | Latigo Biotherapeutics Inc. | Derivative conversion | +3,547,842 | — | — |
| Aug 10, 2026 | Latigo Biotherapeutics Inc. | Derivative conversion | +1,027,635 | — | — |
| Aug 10, 2026 | Latigo Biotherapeutics Inc. | Derivative conversion | +3,464,072 | — | — |
| Aug 10, 2026 | Latigo Biotherapeutics Inc. | Derivative conversion | +1,484,401 | — | — |
| Aug 10, 2026 | Latigo Biotherapeutics Inc. | Derivative conversion | +165,519 | — | — |
| Aug 10, 2026 | Latigo Biotherapeutics Inc. | Derivative conversion | +2,066,857 | — | — |
| May 27, 2026 | Kyverna Therapeutics Inc. | Grant or award | +5,093 | — | — |
| Dec 18, 2025 | Kyverna Therapeutics Inc. | Open-market purchase | +133,333 | $7.50 | $999,998 |
| May 29, 2025 | Kyverna Therapeutics Inc. | Grant or award | +16,634 | — | — |
| Oct 28, 2024 | Vera Therapeutics Inc. | Open-market sale | −14,798 | $48.01 | $710,452 |
| Oct 28, 2024 | Vera Therapeutics Inc. | Open-market sale | −202 | $49.54 | $10,007 |
| Sep 19, 2024 | Vera Therapeutics Inc. | Open-market sale | −13,823 | $42.31 | $584,851 |
| Sep 18, 2024 | Vera Therapeutics Inc. | Open-market sale | −1,177 | $42.01 | $49,446 |
| Sep 18, 2024 | Vera Therapeutics Inc. | Open-market sale | −1,476 | $42.00 | $61,992 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.